{"id":62135,"date":"2026-04-01T23:39:21","date_gmt":"2026-04-01T15:39:21","guid":{"rendered":"https:\/\/flcube.com\/?p=62135"},"modified":"2026-04-01T23:39:23","modified_gmt":"2026-04-01T15:39:23","slug":"changchun-high-new-receives-nmpa-approval-for-gensci161-clinical-study-in-endometriosis-and-hidradenitis-suppurativa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62135","title":{"rendered":"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa"},"content":{"rendered":"\n<p><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced it has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate clinical studies for <strong>GenSci161<\/strong>, a novel <strong>fully human bispecific antibody<\/strong> targeting <strong>interleukin-1 (IL-1)<\/strong> for the treatment of <strong>endometriosis<\/strong> and <strong>moderate-to-severe hidradenitis suppurativa<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Molecule Type<\/strong><\/td><td>Fully human bispecific antibody<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>IL-1\u03b1 and IL-1\u03b2 (dual inhibition)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Neutralizes IL-1\u03b1\/\u03b2 without binding to endogenous IL-1RA<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>OmniMab ultra-long-acting multispecific antibody platform<\/td><\/tr><tr><td><strong>Dosing Interval<\/strong><\/td><td>Subcutaneous administration every 8-12 weeks<\/td><\/tr><tr><td><strong>Key Advantage<\/strong><\/td><td>Preserves body&#8217;s intrinsic regulatory mechanisms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-il-1-targeting\">Dual IL-1 Targeting<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Targets<\/strong>: Simultaneously inhibits IL-1\u03b1 and IL-1\u03b2 subtypes<\/li>\n\n\n\n<li><strong>Downstream Effect<\/strong>: Blocks activation of inflammatory signaling pathways<\/li>\n\n\n\n<li><strong>Selectivity<\/strong>: Does not interfere with endogenous IL-1 receptor antagonist (IL-1RA)<\/li>\n\n\n\n<li><strong>Physiological Preservation<\/strong>: Maintains natural anti-inflammatory regulatory mechanisms<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-extended-half-life-technology\">Extended Half-Life Technology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform<\/strong>: Proprietary OmniMab Fc engineering technology<\/li>\n\n\n\n<li><strong>Dosing Convenience<\/strong>: 8-12 week subcutaneous dosing intervals<\/li>\n\n\n\n<li><strong>Patient Benefit<\/strong>: Reduced treatment burden compared to frequent dosing regimens<\/li>\n\n\n\n<li><strong>Compliance Advantage<\/strong>: Long-acting profile supports chronic disease management<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-indications\">Target Indications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-endometriosis\">Endometriosis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Affects approximately 10% of reproductive-age women globally<\/li>\n\n\n\n<li><strong>Current Treatment<\/strong>: Limited options with significant side effects<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Chronic inflammatory condition requiring long-term systemic therapy<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Large underserved patient population with high disease burden<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-moderate-to-severe-hidradenitis-suppurativa\">Moderate-to-Severe Hidradenitis Suppurativa<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Chronic inflammatory skin disease affecting 1-4% of population<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Biologics like adalimumab approved but with limitations<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Need for more effective and convenient long-term options<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Premium pricing opportunity in dermatology biologics market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-changchun-high-amp-new\">For Changchun High &amp; New<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Demonstrates capabilities of OmniMab multispecific antibody platform<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Expands beyond traditional business into innovative biologics<\/li>\n\n\n\n<li><strong>Technology Leadership<\/strong>: Positions company as advanced biologics developer in China<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Novel mechanism supports potential international development<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-1 Inhibition<\/strong>: Established target with proven efficacy in inflammatory diseases<\/li>\n\n\n\n<li><strong>Dual Targeting Innovation<\/strong>: Differentiated approach versus single IL-1 inhibitors<\/li>\n\n\n\n<li><strong>Dosing Advantage<\/strong>: Extended half-life provides competitive edge over existing biologics<\/li>\n\n\n\n<li><strong>Chinese Biologics Market<\/strong>: Growing acceptance of premium innovative therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-next-steps\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Stage<\/strong>: Phase I\/II studies expected to initiate in 2026<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: NMPA approval enables first-in-human studies in China<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: Potential for international expansion following Chinese clinical data<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Leveraging existing biologics manufacturing capabilities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Inflammatory Disease Market<\/strong>: Global market for inflammatory biologics exceeds $100 billion<\/li>\n\n\n\n<li><strong>Chinese Healthcare Reform<\/strong>: Increasing reimbursement for innovative therapies<\/li>\n\n\n\n<li><strong>Biologics Adoption<\/strong>: Rapid growth in Chinese biologics market with premium pricing acceptance<\/li>\n\n\n\n<li><strong>Women&#8217;s Health Focus<\/strong>: Endometriosis represents significant unmet need with limited treatment options<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential for GenSci161. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-d36e2cde-6a65-48df-8925-a5916e1f682e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d36e2cde-6a65-48df-8925-a5916e1f682e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,24,1171],"class_list":["post-62135","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-rare-orphan-disease-drugs","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical studies for GenSci161, a novel fully human bispecific antibody targeting interleukin-1 (IL-1) for the treatment of endometriosis and moderate-to-severe hidradenitis suppurativa.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62135\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical studies for GenSci161, a novel fully human bispecific antibody targeting interleukin-1 (IL-1) for the treatment of endometriosis and moderate-to-severe hidradenitis suppurativa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62135\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T15:39:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T15:39:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62135#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62135\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa\",\"datePublished\":\"2026-04-01T15:39:21+00:00\",\"dateModified\":\"2026-04-01T15:39:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62135\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Rare \\\/ orphan disease drugs\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62135#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62135\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62135\",\"name\":\"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-01T15:39:21+00:00\",\"dateModified\":\"2026-04-01T15:39:23+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate clinical studies for GenSci161, a novel fully human bispecific antibody targeting interleukin-1 (IL-1) for the treatment of endometriosis and moderate-to-severe hidradenitis suppurativa.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62135#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62135\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62135#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate clinical studies for GenSci161, a novel fully human bispecific antibody targeting interleukin-1 (IL-1) for the treatment of endometriosis and moderate-to-severe hidradenitis suppurativa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62135","og_locale":"en_US","og_type":"article","og_title":"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate clinical studies for GenSci161, a novel fully human bispecific antibody targeting interleukin-1 (IL-1) for the treatment of endometriosis and moderate-to-severe hidradenitis suppurativa.","og_url":"https:\/\/flcube.com\/?p=62135","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T15:39:21+00:00","article_modified_time":"2026-04-01T15:39:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62135#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62135"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa","datePublished":"2026-04-01T15:39:21+00:00","dateModified":"2026-04-01T15:39:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62135"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Changchun High &amp; New Technology Industries","Rare \/ orphan disease drugs","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62135#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62135","url":"https:\/\/flcube.com\/?p=62135","name":"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-01T15:39:21+00:00","dateModified":"2026-04-01T15:39:23+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate clinical studies for GenSci161, a novel fully human bispecific antibody targeting interleukin-1 (IL-1) for the treatment of endometriosis and moderate-to-severe hidradenitis suppurativa.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62135#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62135"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62135#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High &amp; New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62135"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62135\/revisions"}],"predecessor-version":[{"id":62137,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62135\/revisions\/62137"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}